Results of an open trial of cyclosporine in a group of steroido-dependent myasthenic subjects.
9 subjects with myasthenia gravis, chronically treated with prednisone, underwent an open clinical trial with cyclosporine, an immunosuppressive and immunomodulator drug. Preliminary results after one year of treatment show that cyclosporine induces a further improvement of myasthenic symptoms, and that prednisone may be reduced or discontinued without relapse of clinical symptoms. Side effects of cyclosporine are very frequent and largely influence the treatment.
Antonini
G
G
Department of Neuroscience, University of Rome, La Sapienza, Italy.
Bove
R
R
Filippini
C
C
Millefiorini
M
M
D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000032:analysis; D003524:Cyclosporins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000276:immunology; D009460:Neurologic Examination; D011241:Prednisone / Q000627:therapeutic use*; D011950:Receptors, Cholinergic / Q000276:immunology
D001323:Autoantibodies; D003524:Cyclosporins; D011950:Receptors, Cholinergic; D011241:Prednisone